Verge, following trial failure , rebrands its AI drug discovery ambitions - BioPharma Dive
Verge, following trial failure , rebrands its AI drug discovery ambitions. Formerly known as Verge Genomics, the new Verge Labs will help pharma and ...
Read the original at biopharmadive.com ↗
- Topics
- Healthcare
- Tracked via
- “AI Falures”